Elsunersen not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Epileptic Encephalopathy, SCN2A Encephalopathy
- Main trialPhase 3
- “A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy”In the company’s words, NCT07019922 on ClinicalTrials.gov
Other drugs for Epileptic Encephalopathy
- LP352Longboard Pharmaceuticals · Phase 3
- ZorevunersenStoke Therapeutics, Inc · Phase 3
- Clemizole HClEpygenix · Phase 3
- ETX101Encoded Therapeutics · Phase 1/2
- ION337Ionis Pharmaceuticals, Inc. · Phase 1/2
- BMB-101Bright Minds Biosciences · Phase 2
Coming up1
- DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2026 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026